Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Is RTA A New Potential Option For The Treatment Of Hydatid Cysts?
Current treatment of cystic echinococcosis is surgery or percutaneous aspiration, injection and reaspiration (PAIR) using hypertonic saline or ethanol. It is aimed at causing permanent damage to the endocyst - the thin, delicate, and translucid inner membrane that produces the cystic fluid and generates new larval elements able to expand the infestation. Surgery and PAIR on liver and lung can result in biliary or bronchial fistulae, prompted by endocyst detachment; chemical cholangitis or pneumonia, due to passing of hypertonic saline or ethanol into the biliary or bronchial tree; and infection or abscess on the residual cyst cavity.
generic viagra online
Old Diabetes Drug Teaches Experts New Tricks
Research from the Johns Hopkins Children"s Center reveals that the drug most commonly used in type 2 diabetics who don"t need insulin works on a much more basic level than once thought, treating persistently elevated blood sugar - the hallmark of type 2 diabetes - by regulating the genes that control its production.
News of the day
Extreme Sports Not About Risk-taking: Study
Those who think extreme sports are all about risk-taking are missing the point, according to a QUT researcher. Eric Brymer, a lecturer from the School of Human Movement Studies in the Faculty of Health, has been researching whether the element of risk was an important factor among participants in "extreme" sports such as waterfall kayakers, mountain climbers, big wave surfers and B.A.S.E. jumpers.
Public Health

InSite Vision Announces FDA Approval Of New Ophthalmic Product Enabled By InSite's DuraSite® Technology

InSite Vision Incorporated (OTCBB:INSV) announced that Bausch & Lomb has received approval of Besivance™ (besifloxacin ophthalmic suspension) 0.6% for the treatment of bacterial conjunctivitis ("pink eye") in patients one year and older from the U.S. Food and Drug Administration (FDA). Besivance™ is formulated with InSite Vision"s DuraSite® technology, a synthetic polymer delivery vehicle that enhances the retention time of the drug on the surface of the eye. Bausch & Lomb licensed the besifloxacin DuraSite formulation from InSite Vision in 2003 following Phase 1 clinical studies and continued development of this broad-spectrum, anti-infective drop specifically for ophthalmic use. Based on the terms of the agreement, InSite will receive competitive single-digit royalties on global net sales of the product. Besivance is being launched in the U.S. in the second quarter of 2009. The product will be promoted by the sales forces of both Bausch & Lomb and Pfizer, Inc. under a co-promotion agreement involving both companies" prescription ophthalmic pharmaceuticals. "We expect this product to offer patients a valuable therapeutic option for one of the most common ocular conditions worldwide," said Louis Drapeau, InSite"s Chief Executive Officer. "The launch of Besivance represents the second commercially available product incorporating InSite"s DuraSite platform, in addition to AzaSite. This is an exciting milestone which further demonstrates the clinical value of the technology. We continue to look for new opportunities to utilize DuraSite to develop valuable products that treat unmet eye care needs." DuraSite is a synthetic polymer of cross-linked polyacrylic acid that stabilizes small molecules in an aqueous matrix, allowing for targeted and sustained administration. By increasing the time that a therapeutic level of medication remains on the eye"s surface, DuraSite enables a less frequent dosing schedule, increases patient compliance, and increases the therapeutic efficacy. InSite Vision


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009